Axicabtagene ciloleucel

阿基仑赛

Report date: 2026/05/13 20:02:10

Base Information

Drug NameAxicabtagene ciloleucel
Drug Alias NameAnti-CD19-chimeric-antigen-receptor-peripheral-blood-lymphocytes-Kite-Pharma抗人CD19 CAR-T细胞注射液益基利仑赛Anti-CD19-CAR-lentiviral-vector-transduced-autologous-T-cells-Kite-PharmaAxi-cel +[17] 
ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Cell therapy > Source of cells > Blood-derived +[4] 
Mechanisms of ActionB-lymphocyte antigen CD19 modulators
TargetsB-lymphocyte antigen CD19
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Global Approved IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse +[4] 
Approved Indications in ChinaPrimary mediastinal B cell lymphomaLymphoma, Large B-Cell, DiffuseLymphoma, B-Cell
Original Approved Country/TerritoryUnited States
Original Approved Date2017/10/18
Country/TerritoryCzechiaBelgiumCanada +[19] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesCabaret BiotechGilead Sciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesFosun Kite Biotechnology Co., Ltd.Kite PharmaKite Pharma Eu Bv +[8] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaLymphoma, Mantle-CellLymphoma, Follicular +[8] 
Inactive IndicationsN/A

Other Information

ATC CodeL01XX
Related LinksDrugBank